https://www.selleckchem.com/pr....oducts/sotrastaurin-
ation and of tobacco dependence through the relief of nicotine withdrawal symptoms, including cravings. Cancer immunotherapy represents one of the most important innovations in modern medicine. Durvalumab is an anti-programmed cell death ligand1 (PDL-1) agent which is currently under investigation in several studies in combination with the anti-cytotoxic Tlymphocyte-associated protein4 (CTLA-4) drug tremelimumab. The aim of this review was to systematically identify and revise the current scientific literature investigating
Like
Comment
Share
